Jade Biosciences, Inc.
JBIO
$24.71
$0.903.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.74% | 14.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.61% | 24.20% | |||
| Operating Income | -35.61% | -24.20% | |||
| Income Before Tax | -38.16% | -26.60% | |||
| Income Tax Expenses | -6.25% | -72.41% | |||
| Earnings from Continuing Operations | -38.14% | -26.42% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -38.14% | -26.42% | |||
| EBIT | -35.61% | -24.20% | |||
| EBITDA | -35.62% | -24.21% | |||
| EPS Basic | -32.00% | -15.77% | |||
| Normalized Basic EPS | -30.74% | -18.29% | |||
| EPS Diluted | -32.00% | -15.77% | |||
| Normalized Diluted EPS | -30.74% | -18.29% | |||
| Average Basic Shares Outstanding | 5.67% | 7.01% | |||
| Average Diluted Shares Outstanding | 5.67% | 7.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||